Kornimate/medical-research-clean huggingface dataset:
study of duodenal-jejunal bypass(djb) as a potential cure for type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: premise: complete resolution of type 2 diabetes mellitus with normalization of blood glucose and hba1c in the abscence of medication support is possible with a surgical procedure named the "duodenal-jejunal bypass (djb)" a modification of an established duodenal switch procedure and is performed utilizing the laparoscopic approach.

hypothesis: the duodenum plays a major role in glucose homeostasis through mechanisms largely unknown at this time. evidence of this hypothesis comes from accumulated data in bariatric surgery patients who underwent roux-en-y gastric bypass or biliopancreatic diversion (bpd) with or without a duodenal switch. current evidence strongly supports this hypothesis with a long term (over 10 years) type 2 diabetes mellitus(t2dm) resolution rate of 84-86% following the gastric bypass and over 95% for the duodenal switch. the clinical resolution of t2dm is defined as independence of all anti-diabetic medications and maintaining a hba1c less than 6.0. recent rodent experiments by francesco rubino and subsequent human case reports by cohen et al. supports the validity of this hypothesis. the modified procedure involved a roux-en-y bypass of the duodenum and 30-50cm of proximal jejunum, unaltering the stomach and pylorus resulted in resolution of t2dm with no weight loss in all subjects.

Eligibility criteria:
inclusion criteria: * established diagnosis of type 2 diabetes mellitus * body mass index(bmi) less than 35 * insulin usage duration less than 10 years * negative anti-gad * fasting c-peptide level over 1.0 mcg/ml * ability and willingness to follow up for a period of 1 year * willingness to consent for utilizing personal results without individual identifier information to be published in medical studies and other media as determined by the study investigators * ability to understand and describe the risks, benefits and mechanism of action of the procedure exclusion criteria: * current pregnancy or positive pregnancy test * liver cirrhosis * coagulopathy * type 1 diabetes mellitus * hiv * previous abdominal surgery preventing laparoscopy * previous vagotomy * previous gastric or small intestine surgery * inability to comply with study requirements * currently active medical malpractice lawsuit/s * diseases of the exocrine pancreas: pancreatitis trauma, pancreatectomy, neoplasia, cystic fibrosis, hemochromatosis * endocrinopathies: acromegaly, glucagonoma, cushing's syndrome, pheochromocytoma, hyperthyroidism, somatostatinoma, aldorestanoma * chemical induced diabetes: vacor, pentamidine, nicotinic acid, glucocorticoids, thyroid hormones, diazoxide, beta-adrenergic agonists, thiazides, phenytoin, alfa-interferon * genetic syndromes with diabetes: down's, klinefelter's, turner's, wolfram, lawrence-moon- beidel, prader-willi, friederich's ataxia, huntington's chorea, myotonic dystrophy, porphyria, * if a candidate is deemed to be not an appropriate candidate based on investigators recommendation.

Keywords: diabetes mellitus surgery duodenal bypass resolution surgical procedures
an online, compassion intervention for adults with type 1 and type 2 diabetes mellitus (t1dm; t2dm).

Conditions: Type 1 Diabetes; Type 2 Diabetes

Summary: the goal of this research study is to evaluate a programme that is based on compassionate mind training (cmt) over four-weeks. the programme intends to share information and strategies to reduce diabetes distress, self-criticism, and shame, and improve physical health in people who have type 1 and type 2 diabetes mellitus.

this randomised controlled trial (rct) will compare a cmt intervention for people with type 1 and type 2 diabetes mellitus with a waitlist control group who will be given access after the study. the outcome measures will be completed at baseline (week 0), post-intervention (week 4), and at follow-up (week 8).

Eligibility criteria:
inclusion criteria: * resident in the united kingdom; * clinician diagnosed type 1 diabetes mellitus or type 2 diabetes mellitus; * self-managing condition; * diabetes diagnosed over a year ago. exclusion criteria: * diagnosis of gestational diabetes or pre-diabetes. * current severe mental health condition; * currently self-harming or suicidal; * currently engaging in psychological therapy.

Keywords: compassion intervention
effectiveness of group psychotherapy in patients with fibromyalgia syndrome

Conditions: Fibromyalgia Syndrome

Summary: the hypothesis of the study is that group therapy in fibromyalgia patients can provide significant improvement in pain, fatigue, anxiety and depression levels and emotional expressions.

the purpose of our study; to determine the effectiveness of group psychotherapy in the treatment of fibromyalgia syndrome. patients who received 9 weeks of group therapy and those who did not, at the beginning of treatment, at the end of 9 weeks and 6 months after treatment will be evaluated using the short form-36, fibromyalgia impact questionnaire, revised fibromyalgia impact questionnaire, hospital anxiety and depression scale, fatigue severity scale, beck depression inventory, beck anxiety inventory, pain beliefs scale, emotional expression questionnaire, visual analogue scale, childhood trauma questionnaire, 2016 fibromyalgia diagnostic criteria. at the end of the study, individuals are expected to show less depressive symptoms and anxiety symptoms compared to the beginning of the study, and it is thought that their complaints about pain will decrease.

Eligibility criteria:
inclusion criteria: * fibromyalgia syndrome diagnosed according to 2016 fibromyalgia syndrome diagnostic criteria * volunteers between the ages of 18-65 * literate volunteers * volunteering to participate in group work * there is no obstacle to attend the sessions regularly every week exclusion criteria: * who cannot participate in 9-week group therapy * under 18, over 65 years old * confused enough to not be able to complete and understand the scales given cognitively * having serious mental illness (eg psychotic disorder, mental retardation etc.) * illiterate individuals

Keywords: fibromyalgia group therapy group psychotherapy pain depression anxiety
effect of benzalkonium chloride preserved and preservative-free latanoprost eye drops on conjunctival goblet cells

Conditions: Glaucoma; Ocular Hypertension

Summary: a randomized, investigator-blind, interventinal study will compare the effect of benzalkonium-chloride (bak) preserved and preservative-free (pf) eye drops on conjunctival goblet cells.

the investigators will conduct a randomized, investigator-blind, interventinal study on 28 subjects. each subject will apply a benzalkonium-chloride (bak) preserved eye drop (xalatan) in one eye and a preservative-free (pf) eye drop (monoprost) in the other for 3 months. which eye gets which treatment is randomized. before and after treatment a conjunctival print will be made and the effect of the eye drops on goblet cell density will be evaluated along with effect on the intraocular pressure.

Eligibility criteria:
inclusion criteria: 1. age \>18years 2. danish speaking 3. open angle glaucoma or ocular hypertension 4. average intraocular pressure equal to or above 22 mmhg exclusion criteria: a. history of significant eye diseae (including okular trauma) other than open angle glaucoma and ocular hypertension d. treatment with steroids within the last 3 months from inclusion e. significant untreated systemic disease such as hypertension, heart failure, diabetes mellitus, stroke, lung disease and autoimmune diseases. diseases are not reason for exclusion if they are well treated or does not need treatment g. pregnant or breast feeding h. women using unsafe anticonception i. allergy towards trial medication j. patients who cannot cooperate in eye examination k. ocular surface defects l. need for polytherapy in glaucoma treatment
marginprobe 2.0 data collection protocol

Conditions: Breast Cancer

Summary: previous clinical studies with the marginprobe (mp) system demonstrated the mp system diagnostic accuracy for identification of cancerous/abnormal tissue at the margins (≤ 1mm) of the ex-vivo lumpectomy specimen. the current study is a prospective data collection study with the enhanced technology, the mp2.0 system and is aimed at collecting data to optimize the system algorithm/procedure and to subsequently validate the system to demonstrate non-inferiority to the mp1.x system. in this study, mp2.0 system will be used on ex-vivo lumpectomy specimens at the operating room (or). the study will collect a library of case information data using the mp2.0 system in sequential cohorts of a minimum of 50 subjects until the software and procedure are optimized. the final analysis sample size will be determined and outlined in the sap based upon the results of the optimization stage.


Eligibility criteria:
inclusion criteria: 1. women over 18 years of age 2. diagnosed with cancer, undergoing lumpectomy or partial mastectomy procedure 3. signed informed consent form exclusion criteria: 1. undergoing re-excision procedure 2. concurrent infectious disease 3. pregnancy 4. lactation 5. previous surgery in the same site including open biopsy procedure, previous breast reduction or mastopexy in the operated breast 6. prior radiation treatment in the operated breast 7. participating in any other investigational study for either drug or device which can influence collection of valid data under this study

Keywords: marginprobe breast cancer lumpectomy
a german study evaluating the efficacy and the benefit of integrated personalized diabetes management (pdm) for type 2 diabetes patients.

Conditions: Diabetes Mellitus, Type 2

Summary: this study is a german, prospective, multicenter, controlled, cluster-randomized, interventional comparative study evaluating the efficacy and benefits of integrated pdm care by measuring hba1c levels in patients with type 2 diabetes. patients will be randomized into two groups to use accu-chek smartpix software and accu-chek smartpix device.

outcome of both studies (rd001732 and rd001231) will be integrated and additionally reported as pdm-provalue study program (integrated personalized diabetes management) due to the high similarity in study characteristics, design and study results.

Eligibility criteria:
inclusion criteria: * existence of a signed informed consent form (before any study procedure) * diagnosed type 2 diabetes mellitus * age =18 years * insulin therapy for =6 months: bot, sit, ct or ict * hba1c =7.5% within the last 6 weeks before study visit 1 (patient's inclusion) * longer-term diabetes care by the trial site (at least for the duration of the 12-month study participation) * general practitioner is the primary practitioner in the diabetes care of the patient * insured by the statutory health insurance (gkv) as a statutory or voluntarily insured member or as a family co-insured member * willing and able to participate in the study and to follow the study procedures, among other things sufficient command of the german language, spoken and written exclusion criteria: * diabetes treatment by insulin pump therapy (csii) * experience with the use of special software for systematic processing of smbg data, e.g. the accu-chek® smart pix system/software, the accu-chek® 360° software and/or the diabetes software diabass * presence of terminal renal failure / dialysis and/or a loss of sight or a tumor illness * chronic use of steroids in adrenal suppressant doses, of other immuno-modulatory drugs or chemotherapy * known alcohol, drug and medication abuse * known metabolic disorders and/or disorders or therapies that could lead to or have led to wrong measured results (e.g. with the blood glucose measurement) * existing pregnancy, breast-feeding or plan to become pregnant during study participation * physical illness and/or psychological disorder with the result that the patient cannot implement the medical treatment recommendations independently * dependency relationship to the sponsor or to the investigator, e.g. as a professional colleague or family member
asset 2 study: long-term follow-up of a randomised control trial

Conditions: Shoulder Dislocation

Summary: this study aims to measure the long-term efficacy of arthroscopic bankart repair for first-time anterior shoulder dislocation in terms of recurrent instability and functional outcome.

approximately half of patients who experience a dislocation of their shoulder will go on to experience further problems with their shoulder. some people will suffer persisting instability, and notice an uncomfortable feeling of their shoulder wanting to give way. this can occur commonly during active movements such as playing sports or lifting heavy objects. some patients experience recurrent dislocations, and find that their shoulder is so weak that it slips out of joint with little provocation. previous research suggested that this high rate of subsequent shoulder problems can be greatly reduced (although not abolished completely) by surgery performed soon after the first dislocation. ten years ago, there were two different methods which had been popularised: 1. arthroscopic wash-out: the first is to wash out the shoulder joint with a sterile solution through an arthroscope (keyhole surgery) under a general anaesthetic. 2. arthroscopic repair: the second is to repair the torn tissues in the shoulder, again using key-hole surgery techniques under general anaesthetic. a previous clinical trial was undertaken in our unit (2001-2005) which randomised young patients aged under 35 years to one of the two possible treatments (described above). these procedures were not new or experimental. the same arthroscopic repair technique continues to be routinely used in nhs lothian to treat patients who have late problems following a dislocated shoulder. we do not routinely perform wash-outs of the shoulder joint because this is only effective in treating problems that occur at an early stage.this new study intends to build on these findings by asking each of the patient groups to complete a short questionnaire which uses validated outcomes to measure their shoulder function. the aim of the study is to identify if there is a long-term clinical and functional benefit of early arthroscopic shoulder stabilisation in high-risk patients.

Eligibility criteria:
inclusion criteria: * all patients who had previously enrolled in the previous study shall be considered eligible for inclusion. * aged between 25 and 55 years. exclusion criteria: * patients will be excluded from this long-term follow-up if no contact details are available or if they no longer retained the capacity to provide consent to participate in the study
myocardial effects of niv in ohs patients

Conditions: Respiratory Failure Chronic; Obesity Hypoventilation Syndrome; Obstructive Sleep Apnea; Cardiac Output, Low

Summary: chronic effects of noninvasive ventilation on myocardial function in patients with obesity hypoventilation syndrome (ohs) are scarcely understood. the aim of the present study was to evaluate the long-term effects of volume-targeted bilevel-positive airway pressure ventilation (bipap) on cardiac parameters and myocardial biomarkers in patients with ohs.

chronic effects of non- invasive ventilation on myocardial function in patients with obesity hypoventilation syndrome (ohs) are scarcely understood. the aim of the present study was to evaluate the long-term effects of volume-targeted bilevel-positive airway pressure ventilation (bipap) on cardiac parameters and myocardial biomarkers in patients with ohs. clinically stable patients with ohs referred to the tertiary centre for the initiation of long-term bipap therapy were consecutively enrolled in the study. at baseline, all participants underwent overnight cardiorespiratory polygraphy. bipap therapy using volume-targeted spontaneous/timed mode delivered via an oro-nasal mask was initiated. beat-to-beat noninvasive monitoring by impedance cardiography was used to assess heart function at baseline and after 3 and 12 months of bipap use. serum troponin 1, n-terminal pro-b-type natriuretic peptide (ntprobnp), tumor necrosis factor-alpha (tnf-α), and interleukin-6 (il-6) were monitored. potential risks and benefits comprise haemodynamic effects of niv on cardiovascular parameters including cardiac output and stroke volume. the study started 06/2016 and enrolment was finalized in october 2018. the study was funded by grants from the slovak research and development agency under contract no. apvv-16-0158, and vega 1/0220/17 and 1/0393/22 of the ministry of education, slovakia. the main investigator is pavol pobeha, md, phd, co author is ivana paranicova, md, phd and the corresponding author (study coordinator prof. ruzena tkacova, md, phd)

Eligibility criteria:
inclusion criteria: - clinically stable patients with ohs and chronic severe hypercapnia exclusion criteria: * inability to provide written informed consent * neuromuscular diseases * chest wall diseases * metabolic diseases * acute respiratory tract infection * chronic obstructive pulmonary disease (copd) * systolic lv failure as evidenced by lv ejection fraction\<45% on echocardiography

Keywords: respiratory failure obesity hypoventilation syndrome obstructive sleep apnea cardiac output stroke volume
new serological markers for eosinophilic esophagitis

Conditions: Eosinophilic Esophagitis

Summary: the purpose of the study is to investigate if serological parameters such as "extracellular serum-tryptase (st)" and "eosinophilic cationic protein (ecp)" are useful for the diagnosis and surveillance of the eosinophilic esophagitis (ee).

the eosinophilic esophagitis (ee) is chronic inflammatory and immunological disease. the diagnosis of ee is based upon large numbers of eosinophils in the esophagus on histopathologic examination (\> 20 eosinophils per high powered field in at least one specimen) despite acid suppression with a proton-pump-inhibitor (ppi) for at least two weeks. there are no diagnostic serological markers for ee so far, so that the purpose of the study is to investigate serological markers which are established in other allergic diseases.

Eligibility criteria:
inclusion criteria: * histopathological defined eosinophilic esophagitis * age: 18-80 exclusion criteria: * missing consent form * contraindications for performing esophagogastroscopy/taking biopsies of the esophagus
validation of the artificial pancreas diabeloop algorithm in the hospital

Conditions: Type 1 Diabetes

Summary: to assess whether the diabeloop algorithm provides better glycemic control than the usual algorithm of t1d patients on pump therapy: * at meals, with cho roughly assessed by the patient. * during and after physical activity sessions qualified as moderate by the patient. primary endpoint : time within the glycemic reference range. the study will be conduct with 15 patients at the following investigation centers : corbeil hospital, chu of grenoble, and chu of montpellier.

the 15 patients will have 2 visits during 24 hours (day and night), once with their usual algorithm and once with the diabeloop system.

Eligibility criteria:
inclusion criteria: * patient type 1 diabetic for at least one year * patient treated by external insulin pump for at least 6 months * patients with hba1c \<9% * patient affiliated with social security. * patient able to perform two tests of physical activity of 30 minutes (one event in each treatment period); * aged at least 18 years patient; * patient who signed consent exclusion criteria: * all serious disease that could interfere with the study * bmi \> 30 kg/m2 * insulin requirement \> 2 u/kg/day * patient benefiting from a measure of legal protection; * pregnant or likely to be women.

Keywords: glycemic control algorithm closed loop artificial pancreas
effect of pilates exercises and tens acupuncture in primary dysmenorrhea among female students at kau

Conditions: Dysmenorrhea Primary

Summary: this study was done to determine the effect of pilates exercises and tens acupuncture in primary dysmenorrhea among female students at king abdulaziz university (kau).


Eligibility criteria:
inclusion criteria: * participants suffering from primary dysmenorrhea. * their age ranged between 18-24 years * their bmi less than 30 kg/m2. exclusion criteria: * gynecological disorders (secondary dysmenorrhea) * married females, * low back pain due to any other pathology * chronic diseases (diabetes, high blood pressure)
to characterize the safety and tolerability of eculizumab in two japanese ahus patients

Conditions: ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)

Summary: this protocol is intended to formally collect data on the treatment of ahus with eculizumab in japanese patients.


Eligibility criteria:
inclusion criteria: 1. patient and/or legal guardian must be willing and able to give written informed consent and id the patient is not an adult and able to read and write, the patient is willing to give written informed assent 2. eculizumab treatment initiated as personal importation for ahus in 201 exclusion criteria: not applicable
impact of covid-19 aerosol box on intubation success rate

Conditions: Intubation; Difficult or Failed

Summary: the safety of novel medical device must be assessed before being implemented into clinical practice. in the case of aerosol box, one of the safety features concerned includes its impact on intubation and how it affect the probability of efficient intubation in order to avoid risk of hypoxia to patient. as the barrier box is newly invented, there have been limited studies published. this study aims to compare intubation success rate between intubation with and without aerosol box in real patients, which will determine the chances of efficient intubation and reflect the safety features of the aerosol box.

general objective to determine whether intubation performed using aerosol box will have a lower chance of success as compared to intubation without using the box. specific objectives 1. to determine whether intubation with aerosol box will require more time for successful intubation as compared to intubation without the box. 2. to compare the ease of intubation and determine whether intubation using aerosol box will require additional airway manipulation as compared to intubation without using the box.

Eligibility criteria:
inclusion criteria: 1. age \> 18 years old 2. american society of anesthesiologist (asa) i or ii patients 3. tested negative for covid-19 prior to surgery 4. patient scheduled for elective surgery under general anaesthesia exclusion criteria: 1. claustrophobia 2. difficult airway features 3. body mass index (bmi) of more than 35 kg/m2 4. body habitus not physically fit into the aerosol box.